Koti M - Search Results

1

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.

Weberpals JI, Koti M, Squire JA. Weberpals JI, et al. Among authors: koti m. Cancer Genet. 2011 Oct;204(10):525-35. doi: 10.1016/j.cancergen.2011.09.004. Cancer Genet. 2011. PMID: 22137482 Review.

2

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. Haslehurst AM, et al. Among authors: koti m. BMC Cancer. 2012 Mar 19;12:91. doi: 10.1186/1471-2407-12-91. BMC Cancer. 2012. PMID: 22429801 Free PMC article.

3

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA. Koti M, et al. BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549. BMC Cancer. 2013. PMID: 24237932 Free PMC article.

4

Mechanisms of hypoxia-mediated immune escape in cancer.

Barsoum IB, Koti M, Siemens DR, Graham CH. Barsoum IB, et al. Among authors: koti m. Cancer Res. 2014 Dec 15;74(24):7185-90. doi: 10.1158/0008-5472.CAN-14-2598. Epub 2014 Oct 24. Cancer Res. 2014. PMID: 25344227

5

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA. Koti M, et al. Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Br J Cancer. 2015. PMID: 25826225 Free PMC article.

6

Current state of biomarkers in ovarian cancer prognosis.

Au KK, Josahkian JA, Francis JA, Squire JA, Koti M. Au KK, et al. Among authors: koti m. Future Oncol. 2015;11(23):3187-95. doi: 10.2217/fon.15.251. Epub 2015 Nov 9. Future Oncol. 2015. PMID: 26551891 Review.

7

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.

Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AW, Graham CH. Black M, et al. Among authors: koti m. Oncotarget. 2016 Mar 1;7(9):10557-67. doi: 10.18632/oncotarget.7235. Oncotarget. 2016. PMID: 26859684 Free PMC article.

8

STAT1-associated intratumoural T_H1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.

Au KK, Le Page C, Ren R, Meunier L, Clément I, Tyrishkin K, Peterson N, Kendall-Dupont J, Childs T, Francis JA, Graham CH, Craig AW, Squire JA, Mes-Masson AM, Koti M. Au KK, et al. Among authors: koti m. J Pathol Clin Res. 2016 Sep 19;2(4):259-270. doi: 10.1002/cjp2.55. eCollection 2016 Oct. J Pathol Clin Res. 2016. PMID: 27917296 Free PMC article.

9

CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.

K Au K, Peterson N, Truesdell P, Reid-Schachter G, Khalaj K, Ren R, Francis JA, Graham CH, Craig AW, Koti M. K Au K, et al. Among authors: koti m. Gynecol Oncol. 2017 Jun;145(3):436-445. doi: 10.1016/j.ygyno.2017.03.007. Epub 2017 Mar 17. Gynecol Oncol. 2017. PMID: 28318643

10

Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome.

Josahkian JA, Saggioro FP, Vidotto T, Ventura HT, Candido Dos Reis FJ, de Sousa CB, Tiezzi DG, de Andrade JM, Koti M, Squire JA. Josahkian JA, et al. Among authors: koti m. Int J Gynecol Cancer. 2018 Mar;28(3):459-465. doi: 10.1097/IGC.0000000000001193. Int J Gynecol Cancer. 2018. PMID: 29303938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results